095700.KQ Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:30):

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea...

Stats
Šios dienos apimtis	88 896.00
Vidutinė apimtis	219 958
Rinkos kapitalizacija	318.75B
EPS	KRW0 ( 2024-02-08 )
Kita pelno data	( KRW229.00 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW8.67 (0.11%)

Tūris Koreliacija

Ilgas: 0.16 (neutral)

Trumpas: 0.08 (neutral)

Signal:(62.734) Neutral

Genexine, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Genexine, Inc. Koreliacija - Valiuta/Žaliavos

-0.38
( neutral )

-0.41
( neutral )

-0.03
( neutral )

-0.30
( neutral )

0.54
( weak )

Genexine, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	KRW4.43B
Bruto pelnas:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2023
Pajamos:	KRW4.43B
Bruto pelnas:	KRW-4.00B (-90.32 %)
EPS:	KRW-1 652.14

FY	2022
Pajamos:	KRW16.14B
Bruto pelnas:	KRW7.30B (45.26 %)
EPS:	KRW-1 326.23

Financial Reports:

No articles found.

Genexine, Inc.

Genexine, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of immunotherapeutics and long-acting biologics in South Korea. It develops hyFc platform, a proprietary technology designed to drive the discovery of various differentiated agonistic protein therapeutics; and the Immune Enhancing Technology, a therapeutic DNA vaccine technology. The company's product pipeline includes GX-H9, which is in Phase II clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E2, which is in Phase II clinical trials for the treatment of induced anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; and GX-G6 that is in Phase I clinical trials for the treatment of diabetes. It is also developing GX-188E that is in Phase II clinical trials in combination with KEYTRUDA for the treatment of cervical cancer. Genexine, Inc. has a co-development partnership with Binex Co. Ltd. to develop COVID-19 vaccine. The company was formerly known as Genexine Co., Ltd. and changed its name to Genexine, Inc. in March 2013. Genexine, Inc. was founded in 1999 and is based in Seongnam, South Korea.